What is the value of Israeli digital medical data files for each patient, collected over decades, at the value of the world’s leading pharmaceutical companies? Opinions are divided on this topic and changed from time to time. Shortly before and during the streaming epidemic, the prevailing consensus was that the databases gave the Israeli medical sector a great advantage and was a factor that attracts the activities of the leading companies here. These expectations were achieved only in part, but this week’s agreement has been signed, however, it gives hope to benefit from the country’s wealth from knowledge.
Astrazneca launched a beam – healthcare lighting through the Data Center with the Faculty of Public Health, the Faculty of Medicine at Tel Aviv University, the Li -Daitet boxes and the health of the health. This is the second research center of its kind that the company has established in the world.
The center will use the data collected from healthy and unknown insurance companies, and it will allow Astrazneca to use data to better understand the disease mechanisms and new treatment methods and how to improve the quality of the patient’s life. University researchers will help the company to study databases.
In recent years, the ability to analyze data in the real world has improved due to artificial intelligence tools and mathematical strength. Data study in the real world is an important supplementary tool for clinical trials, which makes it possible to understand the effectiveness of medications in patients who suffer from many diseases or elderly patients who have not been included in clinical trials; To test groups of medications or testing methods of testing against each other, not only against a monitoring group that receives a fake treatment. It is also possible to identify rare side effects, distinguish between patients who are expected to respond to treatment or not, or to customize treatment. Databases can also be used to understand the economic value of treatment in a specific group of patients.
The center is headed by Professor Gabriel Hoodik at Tel Aviv University. This is an innovative center in many aspects: “First, in the industry triangle, academic circles and health services that combine forces to enhance medical research and services. Secondly, investing in improving excellent databases of health funds in order to enable them by ensuring that there are complete research research. Data science in the health sector.”
“Through cooperation between academic, industry and health funds, we will be able to enhance in -depth research and data -based learning, understand the best needs of patients today, and develop medical solutions that will benefit them in the future,” added the CEO of Astrazneca Israel Ohad Goldberg.
It was published by Globes, Israel Business News – En.globes.co.il – on April 28, 2025.
© Copy Publish Publisher Itonut (1983) Ltd. , 2025.
The post Astrazeneca sets up Tel Aviv center to study Israeli health data first appeared on Investorempires.com.
